1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29. doi: 10.3322/caac.20138
2. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010; 102: 464-474. doi: 10.1093/jnci/djq025
3. Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): A review. Respir Med. 2010; 104: 1767-1774. doi: 10.1016/j.rmed.2010.08.005
4. Chen HY, Yu SL, Li KC, Yang PC. Biomarkers and transcriptome profiling of lung cancer. Respirology. 2012; 17: 620-626. doi: 10.1111/j.1440-1843.2012.02154.x
5. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285. doi: 10.1097/JTO.0b013e318206a221
6. Holdenrieder S, Stieber P. Circulating apoptotic markers in the management of non-small cell lung cancer. Cancer Biomarkers. 2009; 6: 197-210. doi: 10.3233/CBM-2009-0130
7. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008; 56: 43-53. doi: 10.1007/s11748-007-0211-x
8. Dhillon T, Mauri FA, Bellezza G, et al. Overexpression of the mammalian target of rapamycin: A novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010; 5: 314-319. doi: 10.1097/JTO.0b013e3181ce6604
9. Su WP, Chen YT, Lai WW, Lin CC, Yan JJ, Su WC. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer. 2011; 71: 28-33. doi: 10.1016/j.lungcan.2010.04.009
10. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 2010; 34: 1193-1198. doi: 10.1097/PAS.0b013e3181e5e024
11. van der Drift MA, Hol BEA, Klaassen CHW, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer. 2010; 68: 283-287. doi: 10.1016/j.lungcan.2009.06.021
12. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer. 2010; 71: 209-216. doi: 10.1016/j.lungcan.2010.04.017
13. Liu L, Zhao E, Li C, et al. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. Cancer Epidemiol. 2013; 37: 71-78. doi: 10.1016/j.canep.2012.08.005
14. Singhal S, Miller D, Ramalingam S, Sun SY. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008; 60: 313-324. doi: 10.1016/j.lungcan.2008.03.007
15. Lu Y, Lemon W, Liu PY, Yang P, You M. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006; 3: e467. doi: 10.1371/journal.pone.0030880
16. Ohgino K, Soejima K, Yasuda H, et al. Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer. 2014; 83: 90-96. doi: 10.1016/j.lungcan.2013.10.016
17. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol. 2005; 23: 3219-3226. doi: 10.1200/JCO.2005.15.511
18. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010; 28: 4417-4424. doi: 10.1200/JCO.2009.26.4325
19. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer. 2011; 129: 355-364. doi: 10.1002/ijc.25704
20. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004; 64: 5564-5569. doi: 10.1158/0008-5472.can-04-2004
21. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 2008; 14: 822-827. doi: 10.1038/nm.1790
22. Hokamp K, Roche FM, Acab M, et al. ArrayPipe: a flexible processing pipeline for microarray data. Nucleic Acids Research. 2004; 32: W457-W459. doi: 10.1093/nar/gkh446
23. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004; 3(3). doi: 10.2202/1544-6115.1027
24. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques. 2003; 34: 374-378. doi: 10.2144/03342mt01
25. Kadara H, Lacroix L, Behrens C, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res. 2009; 2: 702-711. doi: 10.1158/1940-6207.CAPR-09-0084
26. Mwenifumbo JC, Marra MA. Cancer genome-sequencing study design. Nat Rev Genet. 2013; 14: 321-332. doi: 10.1038/nrg3445
27. Park SY, Lee JG, Kim J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013; 79: 156-160. doi: 10.1016/j.lungcan.2012.11.006
28. Nanjundan M, Byers LA, Carey MS, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010; 5: 1894-1904. doi: 10.1097/JTO.0b013e3181f2a266
29. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest. 2010; 138: 1173-1179. doi: 10.1378/chest.10-0157
30. Botling J, Edlund K, Lohr M, et al. Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation. Clin Cancer Res. 2013; 19: 194-204. doi: 10.1158/1078-0432.CCR-12-1139
31. Deng S, Wang J, Hou L, et al. Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett. 2013; 5: 107-112. doi:10.3892/ol.2012.959
32. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One. 2010; 5: e8747. doi: 10.1371/journal.pone.0008747
33. Chapin C, Bailey NA, Gonzales LW, Lee JW, Gonzalez RF, Ballard PL. Distribution and surfactant association of carcinoembryonic cell adhesion molecule 6 in human lung. Am J Physiol Lung Cell Mol Physiol. 2012; 302: L216-225. doi: 10.1152/ajplung.00055.2011
34. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013; 3: 2650. doi: 10.1038/srep02650
35. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009; 28: 4456-4468. doi: 10.1038/onc.2009.292
36. Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol. 2010; 49: 861-864. doi: 10.3109/02841861003631503
37. Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010; 116: 4114-4121. doi: 10.1002/cncr.25196
38. Phipps KD, Surette AP, O’Connell PA, Waisman DM. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res. 2011; 71: 6676-6683. doi: 10.1158/0008-5472.CAN-11-1748
39. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res. 2011; 17: 5247-5256. doi: 10.1158/1078-0432.CCR-10-2805
40. Han SS, Kim WJ, Hong Y, et al. RNA sequencing identifies novel markers of non-small cell lung cancer. Lung Cancer. 2014; 84: 229-235. doi: 10.1016/j.lungcan.2014.03.018
41. Morton ML, Bai X, Merry CR, et al. Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. Lung Cancer. 2014; 85: 31-39. doi: 10.1016/j.lungcan.2014.03.020
42. Han SW, Roman J. Anticancer actions of PPARgamma ligands: Current state and future perspectives in human lung cancer. World J Biol Chem. 2010; 1: 31-40. doi: 10.4331%2Fwjbc.v1.i3.31
43. Khan G, Denniss F, Mills KI, Pulford K, Guinn B. PASD1: A promising target for the immunotherapy of haematological malignancies. J Genet Syndr Gene Ther. 2013; 4. doi: 10.4172/2157-7412.1000186
44. Guinn BA, Bland EA, Lodi U, et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun. 2005; 335: 1293-1304. doi: 10.1016/j.bbrc.2005.08.024
45. Calderon MR, Verway M, An BS, et al. Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. J Biol Chem. 2012; 287: 8662-8674. doi: 10.1074/jbc.M111.311605
46.Mertsch S, Schurgers LJ, Weber K, Paulus W, Senner V. Matrix gla protein (MGP): an overexpressed and migration-promoting mesenchymal component in glioblastoma. BMC Cancer. 2009; 9: 302. doi: 10.1186/1471-2407-9-302
47. Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol. 2008; 38: 671-678. doi: 10.1165/rcmb.2007-0205OC
48. Tseng YH, Vicent D, Zhu J, et al. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. Cancer Res. 2001; 61: 2071-2079.
49. Holland SJ, Liao XC, Mendenhall MK, et al. Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling. J Exp Med. 2001; 194: 1263-1276. doi: 10.1084/jem.194.9.1263
50. Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002; 8: 3803-3812.
51. He Y, Zhou Z, Hofstetter WL, et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7: e31087. doi: 10.1371/journal.pone.0031087
52. Koizumi H, Yamada T, Takeuchi S, et al. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 2012; 7: 1078-1085. doi: 10.1097/JTO.0b013e3182519a2c
53. Pei BX, Sun BS, Zhang ZF, Wang AL, Ren P. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2014; 148: 1208-1216. doi: 10.1016/j.jtcvs.2014.05.003
54. Gu J, Ding JY, Lu CL, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer . 2013; 81: 259-265. doi: 10.1016/j.lungcan.2013.04.020
55. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674. doi: 10.1016/j.cell.2011.02.013